• News by Topic

  • News by Topic

  • Relationships news

  • Mind and body

    "Live as if your were to die tomorrow. Learn as if you were to live forever. You must learn to be still in the midst of activity and be vibrantly alive in repose."

    --Gandhi

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.

Vote!

FDA Approves Vraylar for Treatment of Schizophrenia and Bipolar Disorder

The Food and Drug Administration (FDA) last week approved Vraylar (cariprazine), a dopamine D2/D3 receptor partial agonist, as a treatment for schizophrenia and bipolar disorder in adults.The approval was based on a set of six controlled clinical trials that included over 2,700 adults with bipolar disorder or schizophrenia. Vraylar was shown to reduce the symptoms of both disorders compared with placebo, and was fairly well tolerated, with the most commonly reported adverse reactions being extrapyramidal symptoms and restlessness (akathisia).Vraylar is one of the first FDA-approved antipsychotics that has demonstrated efficacy...

read more...

Share |

Published By: Psychiatric News - Monday, 21 September, 2015

Copyright © 2016 Psychology One. All rights reserved. This site is for education & information purposes. This site is not a substitute for professional psychological, medical or psychiatric treatment.